EC
AVTX icon

EntryPoint Capital’s Avalo Therapeutics AVTX Stock Holding History

EntryPoint Capital’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$449K Buy
+30,041
New +$470K 0.13% 292

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EntryPoint Capital's AVTX Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 30,041 shares worth $449K. The stake represents 0.13% of the portfolio and ranks #292 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • EntryPoint Capital held 30,041 shares of Avalo Therapeutics worth $449K as of Q1 2026.
  • Avalo Therapeutics was a new EntryPoint Capital position in Q1 2026.
  • Avalo Therapeutics made up 0.13% of EntryPoint Capital's portfolio in Q1 2026, its #292 holding.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.